1,293 results match your criteria Journal of medical economics[Journal]


Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis.

J Med Econ 2019 Feb 18. Epub 2019 Feb 18.

c Stony Brook University , Stony Brook , NY , USA.

Background Heart failure (HF) is a common, serious disease in the United States and Europe. Patients with HF often require treatment for fluid overload, resulting in costly inpatient visits; however, limited evidence exists on the costs of alternative treatments. This study performed a cost-analysis of ultrafiltration (UF) versus diuretic therapy (DIUR-T) for patients with HF from the hospital perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1584109DOI Listing
February 2019

Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML).

J Med Econ 2019 Feb 18. Epub 2019 Feb 18.

f Jazz Pharmaceuticals, Inc. , Palo Alto , CA , USA.

Aims Acute myeloid leukemia (AML) treatment typically involves remission induction chemotherapy followed by consolidation chemotherapy. New treatments for AML have recently been introduced, including a chemotherapy formulation called CPX-351, which is administered via less time-intensive IV infusion than the standard "7 + 3" continuous infusion regimen of cytarabine plus an anthracycline. The purpose of this study was to estimate utilities that could be used in economic modeling of AML treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1584108DOI Listing
February 2019

The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.

J Med Econ 2019 Feb 13. Epub 2019 Feb 13.

b McMaster University, Department of Clinical Epidemiology and Biostatistics (CEB) , Hamilton , Ontario , Canada.

Background Both public and private insurers provide drug coverage in Canada. All payers are under pressure to contain costs. It has recently been proposed that private plans leverage the public health technology assessment (HTA) evaluation process in their decision-making. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582535DOI Listing
February 2019

The whole is greater than the sum of its parts: the importance of integrated, universal and equitable healthcare coverage.

J Med Econ 2019 Feb 13. Epub 2019 Feb 13.

a Pharmacoepidemiology-Pharmacovigilance, Pharmacy Programme, Department of Life and Health Sciences, School of Sciences and Engineering , University of Nicosia , Nicosia , Cyprus.

Universal Health Coverage entails a universal, equitable and effective provision of comprehensive health services. In this context, socioeconomic attributes have acquired a dominant role as determinants in healthcare coverage. This violates equity, the principal attribute of a health system and creates fragmented pools of patients, thus impeding risk distribution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582536DOI Listing
February 2019

CAR T-cells: Costs, Comparisons and Commentary.

J Med Econ 2019 Feb 12. Epub 2019 Feb 12.

b Canadian Cancer Trials Group.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582059DOI Listing
February 2019

Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance.

J Med Econ 2019 Feb 12. Epub 2019 Feb 12.

e Harvard Business School , Boston , Massachusetts , USA.

Objectives: To determine how overall cost of anticoagulation therapy for warfarin compares with that of Novel Oral Anticoagulants (NOACs). Also, to demonstrate a scientific, comprehensive and an analytical approach to estimate direct costs involved in monitoring and management of anticoagulation therapy for outpatients in academic primary care clinic setting, post initiation of therapy.

Methods: A population-based cross-sectional study was conducted in conjunction with observations of patient care processes between August 2014 and January 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1582058DOI Listing
February 2019
1 Read

Does the critical illness insurance reduce patients' financial burden and benefit the poor more: a comprehensive evaluation in rural area of China.

J Med Econ 2019 Feb 11. Epub 2019 Feb 11.

a School of Medicine and Health Management, Huazhong University of Science and Technology , Wuhan , China.

Background: Critical illness insurance (CII) is one kind of health insurance that is gradually gaining attention worldwide. China implemented CII in 2012 to decrease patients' out-of-pocket (OOP) medical payments. The aims of this study were to determine if the project had positive impacts on relieving financial burden and improving health equity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1581620DOI Listing
February 2019

Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures: a retrospective model based cost analysis.

J Med Econ 2019 Feb 12. Epub 2019 Feb 12.

a Department of Cardiology , Guy's and St Thomas' NHS Foundation Trust , London , UK.

Background And Aims: Infection is a serious and expensive complication of Cardiac Implantable Electronic Device (CIED) procedures. We performed a retrospective based cost analysis to estimate Trust level savings of using the TYRX antibacterial envelope as a primary prevention measure against infection in a tertiary referral centre in South London, United Kingdom.

Methods: A retrospective cohort of heart failure patients with reduced ejection fraction undergoing Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) procedures were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1581621DOI Listing
February 2019

The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.

J Med Econ 2019 Feb 8. Epub 2019 Feb 8.

b Eli Lilly and Company , Indianapolis , IN USA.

Aims: Examine healthcare costs across chronic kidney disease (CKD) stages for US patients with type 2 diabetes (T2D).

Materials And Methods: IQVIA Real World Data Adjudicated Claims linked electronic medical records and insurance claims from January 1, 2012 through March 31, 2017 were used for this retrospective study. Adults diagnosed with T2D and comorbid CKD were included. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1581208DOI Listing
February 2019
3 Reads

Cost-impact of cardiac magnetic resonance imaging with Fast-SENC compared to SPECT in the diagnosis of coronary artery disease in the U.S.

J Med Econ 2019 Feb 7. Epub 2019 Feb 7.

a Avalon Health Economics , Morristown , NJ USA.

Aims: The purpose of this study is to assess the economic cost differences and the associated treatment resource changes between the developing coronary artery disease (CAD) diagnostic tool fast strain-encoded cardiac imaging (Fast-SENC) and the current commonly used stress test single-photon emission computed tomography (SPECT).

Materials And Methods: We first created a 'payer perspective' model consisting of long-term and short-term components that used a hypothetical cohort of patients of average age (60.8 years) presenting with chest pain and suspected CAD to assess cost-impact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1580713DOI Listing
February 2019

Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.

J Med Econ 2019 Feb 7. Epub 2019 Feb 7.

f Sun Yat-sen University , China.

Objectives: This study aimed to analyse 1) the cost-effectiveness of olanzapine orally disintegrating tablet (ODT) compared to olanzapine standard oral tablet (SOT) and 2) the cost-effectiveness of olanzapine-SOT compared to aripiprazole-SOT for patients with schizophrenia in China.

Methods: A microsimulation model was adapted from a healthcare payers' perspective. The model ran over a 1-year time horizon, using quarterly cycles. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1580714DOI Listing
February 2019
1 Read

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

J Med Econ 2019 Feb 7. Epub 2019 Feb 7.

a IQVIA , 3110 Fairview Park Drive, Suite 400 , Falls Church , VA , 22042 , USA.

Introduction: The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the United States. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC) patients with rearrangement of the anaplastic lymphoma kinase (ALK) gene. The objective of this study was to measure the impact of copay assistance on patient cost sharing and treatment patterns in patients prescribed oral ALK inhibitors (ALKis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1580200DOI Listing
February 2019
1 Read

The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records.

J Med Econ 2019 Feb 6. Epub 2019 Feb 6.

a Mallinckrodt Pharmaceuticals, Inc. , 1425 US Route 206 , Bedminster , NJ 07921 , USA.

Objectives: Hepatorenal Syndrome (HRS) is characterized by renal failure in patients with advanced chronic liver disease (CLD) and is the leading cause of hospitalizations in CLD. This study examines the clinical and economic burden, outcomes, and unmet need of HRS treatment in US hospitals.

Method: A retrospective cohort study was conducted based on a large electronic health records database (Cerner HealthFacts) with records for hospitalized HRS patients from January 2009 - June 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1580201DOI Listing
February 2019
2 Reads

A Monte Carlo simulation estimating US hospital cost reductions associated with hypotension control in septic ICU patients.

J Med Econ 2019 Jan 30. Epub 2019 Jan 30.

e Cleveland Clinic , Ohio , USA.

Objective: This economic analysis extends upon a recent epidemiological study to estimate the association between hypotension control and hospital costs for septic patients in US intensive care units (ICUs).

Methods: A Monte Carlo simulation decision analytic model was developed that accounted for the probability of complications-acute kidney injury and mortality-in septic ICU patients and the cost of each health outcome from the hospital perspective. Probabilities of complications were calculated based on observational data from 110 US hospitals for septic ICU patients (n = 8,782) with various levels of hypotension exposure as measured by time-weighted average below mean arterial pressure (TWA-MAP, units: mmHg). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1576695DOI Listing
January 2019
1 Read

A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilisation (HCRU) in schizophrenia.

J Med Econ 2019 Jan 30. Epub 2019 Jan 30.

e Lundbeck, Lundbeck A/S, HEOR , Ottiliavej 9 , 2500 Valby , Denmark.

Aims: There have been no systematic literature reviews (SLRs) evaluating the identified association between outcomes (e.g. clinical, functional, adherence, societal burden) and Quality of Life (QoL) or Healthcare Resource Utilization (HCRU) in schizophrenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1576694DOI Listing
January 2019

The economic burden of depression among adults with rheumatoid arthritis in the United States.

J Med Econ 2019 Feb 5:1-7. Epub 2019 Feb 5.

a Janssen Global Services , Horsham , PA , USA.

Aims: Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to assess healthcare utilization, expenditures, and work productivity among patients with RA with or without depression. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1572015DOI Listing
February 2019
15 Reads

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.

J Med Econ 2019 Jan 21:1-8. Epub 2019 Jan 21.

a Department of Endocrinology & Metabolism , Peking University People's Hospital , Beijing , PR China.

Background And Objective: Dapagliflozin is the first SGLT2 inhibitor available in China, where the disease burden of diabetes and its complications is very heavy. Because a new diabetes treatment strategy for diabetes should consider its cost-effectiveness, compared with an existing treatment, this study aimed to examine the cost-effectiveness between dapagliflozin and metformin treatment in China.

Methods: The Cardiff Diabetes Model (CDM) was used to estimate cost effectiveness and macro- and micro-vascular outcomes of dapagliflozin vs metformin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1570220DOI Listing
January 2019
1 Read

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada.

J Med Econ 2019 Jan 19:1-12. Epub 2019 Jan 19.

e Goeree Consulting Ltd, Hamilton , ON , Canada.

Objectives: To estimate the cost-utility of two trabecular micro-bypass stents (TBS) implantation vs standard of care (SOC) in patients with mild-to-moderate open-angle glaucoma (OAG) in the Canadian healthcare setting.

Methods: The deterioration in visual field (VF) defect over a 15-year time horizon was tracked using a Markov model with Hodapp-Parrish-Anderson stages of glaucoma (mild, moderate, advanced, severe/blind) and death as health states. Meta-analyses of randomized clinical trials were conducted to estimate the pooled reduction in intraocular pressure (IOP) and medication use due to TBS and SOC. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1572013DOI Listing
January 2019
5 Reads

Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.

J Med Econ 2019 Jan 19:1-13. Epub 2019 Jan 19.

a Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences , Naresuan University , Phitsanulok , Thailand.

Aims: Non-adherence is associated with poor clinical outcomes among patients with asthma. While cost-effectiveness analysis (CEA) is increasingly used to inform value assessment of the interventions, most do not take into account adherence in the analyses. This study aims to: (1) Understand the extent of studies considering adherence as part of the economic analyses, and (2) summarize the methods of incorporating adherence in the economic models. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1572014DOI Listing
January 2019
5 Reads

The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.

J Med Econ 2019 Jan 17:1-9. Epub 2019 Jan 17.

b Bristol-Myers Squibb , Lawrenceville , NJ 08648 , USA.

Aims: To estimate real world healthcare costs and resource utilization of rheumatoid arthritis (RA) patients associated with targeted disease modifying anti-rheumatic drugs (tDMARD) switching in general and switching to abatacept specifically.

Materials And Methods: RA patients initiating a tDMARD were identified in IMS PharMetrics Plus health insurance claims data (2010-2016), and outcomes measured included monthly healthcare costs per patient (all-cause, RA-related) and resource utilization (inpatient stays, outpatient visits, emergency department [ED] visits). Generalized linear models were used to assess (i) average monthly costs per patient associated with tDMARD switching, and (ii) among switchers only, costs of switching to abatacept vs tumor necrosis factor inhibitors (TNFi) or other non-TNFi. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1571498DOI Listing
January 2019
10 Reads

Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.

J Med Econ 2019 Jan 17:1-6. Epub 2019 Jan 17.

e UCB Pharma , Athens , Greece.

Background And Aims: Epilepsy is the most common serious neurological disorder worldwide. Approximately 40% of patients with focal epileptic seizures remain uncontrolled with antiepileptic drug (AED) monotherapy or polytherapy. Lacosamide has been recently approved by the European Medicines Agency as monotherapy for the treatment of focal seizures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1571499DOI Listing
January 2019

Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.

J Med Econ 2019 Feb 4:1-7. Epub 2019 Feb 4.

b Health Economics & Outcomes Research, Celgene Corporation , Summit , NJ , USA.

Objective: This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics.

Methods: A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apremilast or biologics between January 1, 2014, and December 31, 2015; had 12 months of pre-index and post-index continuous enrollment in the database; and were biologic-naive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1571500DOI Listing
February 2019

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.

J Med Econ 2019 Jan 16:1-6. Epub 2019 Jan 16.

a Department of Medical Oncology , Cancer Center, West China Hospital, Sichuan University , Chengdu 610041 , PR China.

Purpose: Pembrolizumab was recently approved in several countries as a first-line treatment for patients with PD-L1 positive, non-small cell lung cancer (NSCLC). However, it is expensive. This study aimed to assess the cost-effectiveness of pembrolizumab in treating advanced NSCLC patients with PD-L1 positive cancer in China. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1570221DOI Listing
January 2019
8 Reads

Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.

J Med Econ 2019 Jan 15:1-8. Epub 2019 Jan 15.

a ESiOR Oy , Kuopio , Finland.

Aim: To estimate the drug administration, travelling, and productivity costs associated with infusion or subcutaneous proteasome inhibitor (PI) treatments (specifically carfilzomib and bortezomib) for multiple myeloma (MM) patients in Finland.

Materials And Methods: Price tariffs of Finnish hospital districts are used as the basis of invoicing sent to healthcare service payers. A review of these price tariff lists was conducted and obtained data analysed to estimate the mean unit cost of PI administration visit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1569457DOI Listing
January 2019
1 Read

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.

J Med Econ 2019 Jan 14:1-14. Epub 2019 Jan 14.

a Wickenstones Ltd , Didcot , UK.

Background: Model structure, despite being a key source of uncertainty in economic evaluations, is often not treated as a priority for model development. In oncology, partitioned survival models (PSMs) and Markov models, both types of cohort model, are commonly used, but patient responses to newer immuno-oncology (I-O) agents suggest that more innovative model frameworks should be explored.

Objective: A discussion of the theoretical pros and cons of cohort level vs patient level simulation (PLS) models provides the background for an illustrative comparison of I-O therapies, namely nivolumab/ipilimumab combination and ipilimumab alone using patient level data from the CheckMate 067 trial in metastatic melanoma. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2019.1569446DOI Listing
January 2019
7 Reads

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.

J Med Econ 2019 Jan 15:1-10. Epub 2019 Jan 15.

a Unit of PharmacoTherapy, -Epidemiology & -Economics , University of Groningen, Groningen Research Institute of Pharmacy (GRIP) , Groningen , the Netherlands.

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in international guidelines as important alternatives to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (NVAF). Meanwhile, in the Netherlands, NOACs are widely used next to VKAs. The objective of this study is to estimate the cost-effectiveness of treatment with rivaroxaban compared to VKAs in NVAF and VTE patients in the Netherlands, using data from international prospective observational phase IV studies. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1563404DOI Listing
January 2019
1 Read

Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.

J Med Econ 2018 Dec 24:1-9. Epub 2018 Dec 24.

b Value Evidence and Outcomes , GlaxoSmithKline , Collegeville , PA , USA.

Aims: Muscle weakness (MW)-attributable healthcare resource utilization (HCRU) and costs in patients with chronic obstructive pulmonary disease (COPD) have not been well-characterized in US insurance claims databases. The primary objective of this study was to estimate HCRU in patients with evidence of COPD with and without MW diagnosis codes.

Materials And Methods: This retrospective analysis used the MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1563414DOI Listing
December 2018
1 Read

Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.

J Med Econ 2019 Mar 11;22(3):280-287. Epub 2019 Jan 11.

a Analysis Group Inc. , Montréal , Québec , Canada.

Aims: To model direct medical costs associated with reductions in cardiovascular disease (CVD) events in T2DM patients reported in the CANVAS and EMPA-REG trials, which assessed the cardiovascular safety of canagliflozin and empagliflozin, respectively.

Materials And Methods: Costs were modeled from a US managed care organization (MCO) perspective for the CVD outcomes included in both trials: three-point major adverse cardiovascular event (MACE) and its components (cardiovascular-related death, nonfatal myocardial infarction, nonfatal stroke), as well as heart failure requiring hospitalization. The rate of CVD events averted (difference between study drug and placebo) was projected to the portion of an MCO T2DM population matching the respective trial's inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1562817DOI Listing

Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in IRAN.

J Med Econ 2018 Dec 18. Epub 2018 Dec 18.

d Health Human Resources Research Center, School of Management and Medical Information Sciences, Shiraz University of Medical Sciences , Shiraz , Iran.

Aims: Multiple sclerosis (MS) is a chronic, autoimmune and inflammatory disease. If the first-line medicines are not effective enough, specialists will prescribe second-line medicines, such as natalizumab and fingolimod. This study aimed to compare the cost-effectiveness and cost-utility of fingolimod with those of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) in Iran, Fars province in 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1560750DOI Listing
December 2018

Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.

J Med Econ 2019 Mar 14;22(3):273-279. Epub 2019 Jan 14.

a School of Pharmacy , Monash University Malaysia , Bandar Sunway , Selangor , Malaysia.

Background: Very few data are available to demonstrate the economic benefit of early paliperidone palmitate once-monthly long-acting injectable (PP1M) treatment in patients with schizophrenia or schizoaffective disorder.

Methods And Materials: This study has retrospectively compared the healthcare utilization and associated costs of pre- and post-PPIM treatment in 413 patients with schizophrenia or schizoaffective disorder recruited from three major public hospitals providing psychiatric services in Hong Kong. Patients were categorized into early treatment (≤3 years since diagnosis) and chronic (>3 years) groups, and also whether they were receiving polypharmacy (POP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1560749DOI Listing
March 2019
1 Read

Measurement of patient-reported outcomes. 2: Are current measures failing us?

J Med Econ 2018 Dec 17. Epub 2018 Dec 17.

a Galen Research Ltd , Manchester , UK.

All instruments designed to measure latent (unobservable) variables, such as patient-reported outcomes (PROs), have three major requirements; a coherent construct theory, a specification equation and the applications of an appropriate response model. The theory guides the selection of content for the questionnaire and the specification equation links the construct theory to scores produced with the instrument. For the specification equation to perform this role, the patient-reported outcome measure (PROM) must employ a response model that generates values for its individual items. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1560304DOI Listing
December 2018

Measurement of patient-reported outcomes. 1: The search for the Holy Grail.

J Med Econ 2018 Dec 17. Epub 2018 Dec 17.

c MetaMetrics Inc , Durham NC , USA.

Patient-reported outcome measures (PROMs) are used to collect information directly from patients. They may cover several different types of outcomes ranging from symptoms, functioning, utility, satisfaction through to quality of life (QoL). They generally consist of self-completed questionnaires that can be administered by means of hard copies or in a range of electronic formats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1560303DOI Listing
December 2018

The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.

J Med Econ 2019 Mar 9;22(3):254-265. Epub 2019 Jan 9.

e Market Access, Health Economics and Outcomes Research, Bayer Yakuhin, Ltd , Tokyo , Japan.

Aims: To estimate the impact of anti-vascular endothelial growth factor (VEGF) agents on visual impairment and blindness avoided in patients with diabetic macular edema (DME) and on associated patient and caregiver productivity loss in Japan.

Methods: This study compared the impact of current care (estimated at 53.8% utilization of anti-VEGF agents using current data) with that of hypothetical care (characterized by a higher utilization of anti-VEGF agents [80. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1558867DOI Listing
March 2019
13 Reads

Decrease in American birth rates makes it imperative for the United States to implement state mandated fertility coverage.

J Med Econ 2019 Mar 4;22(3):252-253. Epub 2019 Jan 4.

a McGill University Reproductive Center , 888 Boulevard de Maisonneuve East , Montréal , Quebec , Canada.

In recent years, the prevalence of infertility has increased due to delayed childbearing and an increase in the rate of male infertility. Given the high cost of fertility treatment, this option is not valid for families with a low income, and those who can afford it usually choose to have multiple embryo transfer, which has led to an increase in multiple birth rates and an increase in the cost of perinatal care. Due to the expected increase in infertility and decrease in the national live birth rate, the US should set a plan to fund infertility treatment and lead a policy for single embryo transfer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1558866DOI Listing

Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients.

J Med Econ 2018 Dec 14:1-8. Epub 2018 Dec 14.

d ESSEC Business School , Cergy Pontoise , France.

Objective: Transcatheter aortic valve implantation (TAVI) has become the therapy of choice for treating severe aortic stenosis in patients at high-risk for surgery or where it is considered too risky to attempt. This uptake varies across geographies however, and its cost or value has frequently been cited as the reason for this. We sought to evaluate the potential cost and clinical impact of TAVI in intermediate risk patients from a French collective perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1559600DOI Listing
December 2018
1 Read

Constructing a value-based healthcare system for hypertensive patients through changing payment mode: evidence from a comparative study in rural China.

J Med Econ 2019 Mar 17;22(3):245-251. Epub 2019 Jan 17.

e College of Public Health , Zhengzhou University , Zhengzhou , China.

Objective: To construct a value-based healthcare system for rural Chinese hypertensive patients through an increasing outpatient care reimbursement ratio.

Methods: This comparative study sampled two similar counties, Dangyang County and Zhijiang County, in Hubei Province of China, as the intervention group and the control group, respectively. The Social Health Insurance Fund of the intervention group budgeted 600 yuan per capita per year to insured patients with third stage hypertension to cover their outpatient expenditures, while the outpatient expenditures of the control group were not covered by its Social Health Insurance Fund. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1558864DOI Listing
March 2019
6 Reads

Hospital patients with severe wounds: early evidence on the impact of Medicare payment changes on treatment patterns and outcomes.

J Med Econ 2019 Mar 5;22(3):266-272. Epub 2019 Jan 5.

a KNG Health Consulting, LLC, Rockville, MD, USA.

Aims: This study examines the effects of recent changes in Medicare long-term care hospital (LTCH) payments on treatment patterns and outcomes for severe wound patients discharged from short-term acute care hospitals (STACHs).

Materials And Methods: The rolling implementation of a new Medicare payment policy was used to develop a difference-in-difference model. The study population consisted of Medicare beneficiaries subjected to the payment policy changes and hospitalized for stage 3, 4, or unstageable wounds; non-healing surgical wounds; and fistula. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1559599DOI Listing

The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.

J Med Econ 2019 Feb 3;22(2):196-203. Epub 2019 Jan 3.

a Analysis Group, Inc. , Montréal, Québec, Canada.

Objective: To evaluate the impact of comorbidities on healthcare resource use (HRU), and direct and indirect work-loss-related costs in psoriasis patients.

Methods: Adults with psoriasis (≥2 diagnoses, the first designated as the index date) and non-psoriasis controls (no psoriasis diagnoses, randomly generated index date) were identified in a US healthcare claims database of privately-insured patients (data between January 2010 and March 2017 were used). Psoriasis patients were stratified based on the number of psoriasis-related comorbidities (0, 1-2, or ≥3) developed during the 12 months post-index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1557201DOI Listing
February 2019

An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery (SANICS II study).

J Med Econ 2019 Mar 21;22(3):238-244. Epub 2018 Dec 21.

a Department of Health Services Research, CAPHRI School for Public Health and Primary Care , Maastricht University , Maastricht , The Netherlands.

Aims: The objective of this (trial based) economic evaluation was to assess, from a societal perspective, the cost-effectiveness of perioperative enteral nutrition compared with standard care in patients undergoing colorectal surgery.

Materials And Methods: Alongside the SANICS II randomized controlled trial, global quality-of-life, utilities (measured by EQ-5D-5L), healthcare costs, production losses, and patient and family costs were assessed at baseline, 3 months, and 6 months. Incremental cost-effectiveness ratios (ICERs) (i. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1557200DOI Listing
March 2019
6 Reads

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.

Authors:
Lei Wu Lixian Zhong

J Med Econ 2019 Feb 4;22(2):187-195. Epub 2019 Jan 4.

a Irma Lerma Rangel College of Pharmacy , Texas A&M University , College Station , TX , USA.

Aims: This study aimed to evaluate the budget impact of niraparib and olaparib in patients with platinum-sensitive, recurrent ovarian cancer from a US third party payer perspective.

Materials And Methods: A budget impact model was constructed to assess the additional per member per month (PMPM) costs associated with the introduction of niraparib and olaparib, two poly ADP-ribose polymerase ribose polymerase (PARP) inhibitors recently approved to be used in platinum-sensitive, recurrent ovarian cancer patients with and without a gBRCA mutation. The model assessed both pharmacy costs and medical costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1557199DOI Listing
February 2019

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.

J Med Econ 2019 Mar 21;22(3):226-237. Epub 2018 Dec 21.

d Department of Neurology , Medical University of Innsbruck , Innsbruck , Austria.

Background: Multiple sclerosis (MS), a chronic progressive, demyelinating, inflammatory disease, affects 2.5 million people worldwide. Approximately 63% of cases are classified as relapsing-remitting MS (RRMS) at the time of diagnosis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1556668DOI Listing
March 2019
7 Reads

A discrete-choice experiment to assess treatment modality preferences of patients with depression.

J Med Econ 2019 Feb 22;22(2):178-186. Epub 2018 Dec 22.

c Department of Health Services Research , CAPHRI Care and Public Health Research Institute, Maastricht University , The Netherlands.

Aims: There is an increasing interest in understanding patients' preferences in the area of healthcare decision-making to better match treatment with patients' preferences and improve treatment uptake and adherence. The aim of this study was to elicit the preferences of patients with a depressive disorder regarding treatment modalities.

Materials And Methods: In a discrete-choice experiment, patients chose repetitively between two hypothetical depression treatments that varied in four treatment attributes: waiting time until the start of treatment, treatment intensity, level of digitalization, and group size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1555404DOI Listing
February 2019
1 Read

A discrete-choice experiment to assess treatment modality preferences of patients with anxiety disorder.

J Med Econ 2019 Feb 22;22(2):169-177. Epub 2018 Dec 22.

c Department of Health Services Research , CAPHRI Care and Public Health Research Institute, Maastricht University , Maastricht , The Netherlands.

Aims: The aim of this study was to elicit the preference of patients with an anxiety disorder regarding treatment modalities. Understanding patients' preferences could help optimize treatment uptake and adherence to therapeutic interventions.

Materials And Methods: A discrete-choice experiment was used to elicit patients' preferences with regard to four treatment characteristics: waiting time until first treatment, intensity of treatment, face-to-face vs digital treatment, and group size. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1555403DOI Listing
February 2019
3 Reads

Correction.

Authors:

J Med Econ 2018 Dec;21(12):1255

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1550241DOI Listing
December 2018

Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.

J Med Econ 2019 Mar 12;22(3):215-225. Epub 2018 Dec 12.

d Formerly at AbbVie Ltd.

Aims: To carry out a cost-utility analysis comparing the cost-effectiveness of levodopa carbidopa intestinal gel (LCIG) with standard of care (SOC) in patients with advanced Parkinson's Disease (aPD) unsuitable for apomorphine or deep brain stimulation (DBS). LCIG is the only treatment option in this small, but clinically important, population.

Methods: A Markov model with 25 disease states based on disease stage and off-time status plus death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1553179DOI Listing
March 2019
1 Read

Comparison of statistical analysis methods for object case best-worst scaling.

J Med Econ 2018 Nov 27:1-14. Epub 2018 Nov 27.

a Department of Health Services Research , Care and Public Health Research Institute (CAPHRI), Maastricht University , The Netherlands.

Aims: Different methods have been used to analyse 'object case' best-worst scaling (BWS). This study aims to compare the most common statistical analysis methods for object case BWS (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1553781DOI Listing
November 2018

Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.

J Med Econ 2019 Feb 13;22(2):163-168. Epub 2018 Dec 13.

d Carapinha & Company , Boston , MA , USA.

Background: In light of constrained budgets and the need to fund efficient treatment options, this study set out to assess the cost-effectiveness of sorafenib as a first-line treatment of hepatocellular carcinoma (HCC) compared to best supportive care (BSC) from the military hospital perspective in Egypt.

Methods: A decision analytic Markov model simulated disease progression with clinical parameters and utility values derived from published data. Data on direct medical costs were collected from the local healthcare system or payer. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13696998.2018.1
Publisher Site
http://dx.doi.org/10.1080/13696998.2018.1552432DOI Listing
February 2019
16 Reads

Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

J Med Econ 2019 Feb 4;22(2):151-157. Epub 2018 Dec 4.

d South Karelia Social and Health Care District (Eksote) , Lappeenranta , Finland.

Background: Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TNF-alpha biologic secukinumab (fully human IL-17A-inhibitor) vs adalimumab (TNF-alpha-inhibitor) in the treatment of AS in Finland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2018.1551227DOI Listing
February 2019
2 Reads